ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Decitabine

Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.

Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.

Drug pageDecitabine: every studyMany companies study it; this page follows only the 28 they lead. All 277 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 5, 200928 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only90 open or runningphase 4since Nov 5, 2009Nov 28, 2005none ahead
Otsuka82 open or runningphase 3since Aug 8, 2002Jul 19, 2002none ahead
EpiDestinyits history only30 open or runningphase 1since Jan 31, 2019Jan 31, 2019none ahead
Johnson & Johnsonits history only30 open or runningphase 2since Aug 29, 2008Aug 29, 2008none ahead
AbbVieits history only10 open or runningphase 3since May 3, 2019May 3, 2019none ahead
Dong Wha Pharmaceuticalits history only10 open or runningphase 1since Sep 8, 2017Sep 8, 2017none ahead
Imunopharm Technologyits history only10 open or runningphase 1since May 14, 2018May 14, 2018none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 4since Dec 9, 2013Dec 9, 2013none ahead
Treebough Therapiesits history only11 open or runningphase 1since May 20, 2025May 20, 2025Dec 30, 2026phase 1 · NCT07006025

Also a collaborator on its studies: dsm-firmenich.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2002First studies: 3 phase 2 studies in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT00042016, NCT00042003, NCT00041990
  2. Aug 8, 2002Phase 3 study in Myelodysplastic SyndromesNCT00043381 · 160 enrolled · United States
  3. Mar 20, 2014Phase 2 study in Myelodysplastic SyndromesNCT02103478 · 130 enrolled · United States, Canada
  4. May 23, 2022Phase 1 study in Lymphoma, T-Cell, PeripheralNCT05403450 · 33 enrolled · United States, Australia, France and more
  5. Apr 25, 2023Phase 3 study in Myelodysplastic SyndromesNCT05883956 · 13 enrolled · Australia, New Zealand
  6. Sep 22, 2023Phase 2 study in Myelodysplastic SyndromesNCT06091267 · 72 enrolled · China

TargetBeta

“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

All 8 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06091267Myelodysplastic Syndromes · China2Active, not recruitingMay 22, 202672
NCT05883956Myelodysplastic Syndromes · Australia, New Zealand3Active, not recruitingDec 6, 202413
NCT05403450Lymphoma, T-Cell, Peripheral · United States, Australia, France and more1TerminatedDec 16, 202433
NCT02103478Myelodysplastic Syndromes · United States, Canada2CompletedJun 5, 2018130
NCT00043381Myelodysplastic Syndromes · United States3CompletedNov 2002160
NCT00042016Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2Completed40
NCT00042003Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2CompletedDec 200440
NCT00041990Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2Completed40

How it is read

Names in the registry

  • “Decitabine”, 14 entries
  • “decitabine”, 8 entries
  • “decitabine (5-aza-2'deoxycytidine)”, 4 entries
  • “IV Decitabine”, 1 entry
  • “Decitabine + Cedazuridine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.